ReviewFrontiers in immunology2019
Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Unveiling the role of NAD glycohydrolase CD38 in aging and age-related diseases: insights from bibliometric analysis and comprehensive review.Frontiers in immunology · 2025Pooled it
- Linking CD38 Cell Surface Expression to the Unique Calcium Flux Properties in Human Peripheral B Lymphocytes Following anti-IgM and anti-IgG Stimulation.Journal of immunology research · 2026Article
- CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them.HemaSphere · 2023Review
- Overexpression of Potential Markers of Regulatory and Exhausted CD8International journal of molecular sciences · 2023Article
- The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.Frontiers in immunology · 2023Review
- Genetic polymorphisms of bone marrow stromal cell antigen-1 (BST-1/CD157): implications for immune/inflammatory dysfunction in neuropsychiatric disorders.Frontiers in immunology · 2023Review
- Lymphocytes from B-acute lymphoblastic leukemia patients present differential regulation of the adenosinergic axis depending on risk stratification.Discover oncology · 2022Article
- Review
- Article
- Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.Blood cancer journal · 2022Article
- Purinergic signaling: A new front-line determinant of resistance and susceptibility in leishmaniasis.Biomedical journal · 2022Review
- Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.Frontiers in immunology · 2022Article
- Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease.International journal of molecular sciences · 2021Review
- Increased frequency of TIGITOncoimmunology · 2021Article
- Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.Biochemical pharmacology · 2021Review
- In Search of a Role for Extracellular Purine Enzymes in Bone Function.Biomolecules · 2021Review
- Enzymology of extracellular NAD metabolism.Cellular and molecular life sciences : CMLS · 2021Review
- Mono(ADP-ribosyl)ation Enzymes and NADCells · 2021Review
- Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells.Frontiers in immunology · 2021Article
- The Extracellular NADome Modulates Immune Responses.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia develops as the result of intrinsic features of the transformed cell, such as gene mutations and derived oncogenic signaling, and extrinsic factors, such as a tumor-friendly, immunosuppressed microenvironment, predominantly in the lymph nodes and the bone marrow. There, high extracellular levels of nucleotides, mainly NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.